John Milligan is to stand down as CEO of Gilead Sciences Inc. at the end of the year. Former CEO and current chair John Martin will also stand down upon the appointment of a new CEO. Milligan said he was looking forward to a "well-deserved break" and would then move on to "new and different opportunities". (Also see "Milligan’s Retirement Means New CEO For New Gilead" - Scrip, 26 July, 2018.)
Senior departures have also been announced at Amgen Inc., where executive vice president of research and development Sean Harper and executive vice president of global commercial operations Anthony Hooper are retiring. Harper will be succeeded by David Reese, hitherto senior vice president of translational sciences and oncology, with immediate effect, although he will remain at the company for a period to facilitate the transition
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?